Is Mainz Biomed Stock a Good Investment?
Mainz Biomed Investment Advice | MYNZ |
- Examine Mainz Biomed's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Mainz Biomed's leadership team and their track record. Good management can help Mainz Biomed navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Mainz Biomed's business and its evolving consumer preferences.
- Compare Mainz Biomed's performance and market position to its competitors. Analyze how Mainz Biomed is positioned in terms of product offerings, innovation, and market share.
- Check if Mainz Biomed pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Mainz Biomed's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Mainz Biomed BV stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Mainz Biomed BV is a good investment.
Sell | Buy |
Hold
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Hold | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Mainz Biomed Stock
Researching Mainz Biomed's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The company has price-to-book ratio of 1.72. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Mainz Biomed BV recorded a loss per share of 44.4. The entity had not issued any dividends in recent years. The firm had 1:40 split on the 3rd of December 2024.
To determine if Mainz Biomed is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Mainz Biomed's research are outlined below:
| Mainz Biomed BV is way too risky over 90 days horizon | |
| Mainz Biomed BV appears to be risky and price may revert if volatility continues | |
| Mainz Biomed BV has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 895.48 K. Net Loss for the year was (26.3 M) with profit before overhead, payroll, taxes, and interest of 540.96 K. | |
| Mainz Biomed BV currently holds about 26.01 M in cash with (21.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Mainz Biomed BV has a poor financial position based on the latest SEC disclosures | |
| Latest headline from gurufocus.com: Mainz Biomed Expands into Switzerland with labor team w |
Mainz Biomed uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Mainz Biomed BV. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Mainz Biomed's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of April 2024 Upcoming Quarterly Report | View | |
| 21st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Mainz Biomed's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Mainz Biomed's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-03-06 | 2023-12-31 | -0.3167 | -0.24 | 0.0767 | 24 | ||
2024-04-09 | 2024-03-31 | -0.32 | -0.24 | 0.08 | 25 | ||
2023-11-16 | 2023-09-30 | -0.47 | -0.39 | 0.08 | 17 | ||
2023-08-15 | 2023-06-30 | -0.42 | -0.56 | -0.14 | 33 | ||
2022-05-02 | 2022-03-31 | -0.49 | -0.84 | -0.35 | 71 |
Mainz Biomed Target Price Consensus
Mainz target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Mainz Biomed's target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Hold |
Most Mainz analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Mainz stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Mainz Biomed BV, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationMainz Biomed Target Price Projection
Mainz Biomed's current and average target prices are 5.31 and 2.00, respectively. The current price of Mainz Biomed is the price at which Mainz Biomed BV is currently trading. On the other hand, Mainz Biomed's target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Mainz Biomed Market Quote on 25th of February 2025
Target Price
Analyst Consensus On Mainz Biomed Target Price
Mainz Biomed Analyst Ratings
Mainz Biomed's analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Mainz Biomed stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Mainz Biomed's financials, market performance, and future outlook by experienced professionals. Mainz Biomed's historical ratings below, therefore, can serve as a valuable tool for investors.Know Mainz Biomed's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Mainz Biomed is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Mainz Biomed BV backward and forwards among themselves. Mainz Biomed's institutional investor refers to the entity that pools money to purchase Mainz Biomed's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Armistice Capital, Llc | 2024-12-31 | 222 K | Virtu Financial Llc | 2024-12-31 | 18.3 K | Ubs Group Ag | 2024-12-31 | 3.8 K | Citigroup Inc | 2024-12-31 | 673 | Newbridge Financial Services Group, Inc. | 2024-12-31 | 500 | Sbi Securities Co Ltd | 2024-12-31 | 61.0 | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 4.0 |
Mainz Biomed's market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.42 M.Market Cap |
|
Mainz Biomed's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (2.52) | (2.64) | |
| Return On Capital Employed | (4.96) | (4.72) | |
| Return On Assets | (1.96) | (2.06) | |
| Return On Equity | (9.31) | (8.84) |
Determining Mainz Biomed's profitability involves analyzing its financial statements and using various financial metrics to determine if Mainz Biomed is a good buy. For example, gross profit margin measures Mainz Biomed's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Mainz Biomed's profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Mainz Biomed's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Mainz Biomed BV. Check Mainz Biomed's Beneish M Score to see the likelihood of Mainz Biomed's management manipulating its earnings.
Evaluate Mainz Biomed's management efficiency
Mainz Biomed BV has return on total asset (ROA) of (0.9924) % which means that it has lost $0.9924 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (43.3371) %, meaning that it created substantial loss on money invested by shareholders. Mainz Biomed's management efficiency ratios could be used to measure how well Mainz Biomed manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -2.64 in 2025. Return On Capital Employed is likely to rise to -4.72 in 2025. At this time, Mainz Biomed's Non Current Assets Total are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 7.7 M in 2025, whereas Total Assets are likely to drop slightly above 10.4 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.18 | 0.22 | |
| Tangible Book Value Per Share | (0.01) | (0.01) | |
| Enterprise Value Over EBITDA | (27.13) | (28.49) | |
| Price Book Value Ratio | 208.75 | 219.19 | |
| Enterprise Value Multiple | (27.13) | (28.49) | |
| Price Fair Value | 208.75 | 219.19 | |
| Enterprise Value | 867.1 M | 823.7 M |
Leadership effectiveness at Mainz Biomed BV is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 0.32 |
Basic technical analysis of Mainz Stock
As of the 25th of February, Mainz Biomed secures the Risk Adjusted Performance of 0.1002, mean deviation of 100.28, and Downside Deviation of 9.08. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Mainz Biomed BV, as well as the relationship between them.Mainz Biomed's Outstanding Corporate Bonds
Mainz Biomed issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Mainz Biomed BV uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Mainz bonds can be classified according to their maturity, which is the date when Mainz Biomed BV has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Mainz Biomed's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Mainz Biomed's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1002 | |||
| Market Risk Adjusted Performance | 0.7759 | |||
| Mean Deviation | 100.28 | |||
| Semi Deviation | 7.29 | |||
| Downside Deviation | 9.08 | |||
| Coefficient Of Variation | 814.13 | |||
| Standard Deviation | 413.72 | |||
| Variance | 171167.07 | |||
| Information Ratio | 0.1228 | |||
| Jensen Alpha | 51.13 | |||
| Total Risk Alpha | 53.53 | |||
| Sortino Ratio | 5.6 | |||
| Treynor Ratio | 0.7659 | |||
| Maximum Drawdown | 3385.75 | |||
| Value At Risk | (14.48) | |||
| Potential Upside | 15.75 | |||
| Downside Variance | 82.43 | |||
| Semi Variance | 53.12 | |||
| Expected Short fall | (128.44) | |||
| Skewness | 8.12 | |||
| Kurtosis | 65.92 |
| Risk Adjusted Performance | 0.1002 | |||
| Market Risk Adjusted Performance | 0.7759 | |||
| Mean Deviation | 100.28 | |||
| Semi Deviation | 7.29 | |||
| Downside Deviation | 9.08 | |||
| Coefficient Of Variation | 814.13 | |||
| Standard Deviation | 413.72 | |||
| Variance | 171167.07 | |||
| Information Ratio | 0.1228 | |||
| Jensen Alpha | 51.13 | |||
| Total Risk Alpha | 53.53 | |||
| Sortino Ratio | 5.6 | |||
| Treynor Ratio | 0.7659 | |||
| Maximum Drawdown | 3385.75 | |||
| Value At Risk | (14.48) | |||
| Potential Upside | 15.75 | |||
| Downside Variance | 82.43 | |||
| Semi Variance | 53.12 | |||
| Expected Short fall | (128.44) | |||
| Skewness | 8.12 | |||
| Kurtosis | 65.92 |
Consider Mainz Biomed's intraday indicators
Mainz Biomed intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Mainz Biomed stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.94 | |||
| Day Median Price | 5.31 | |||
| Day Typical Price | 5.31 | |||
| Price Action Indicator | (0.18) | |||
| Period Momentum Indicator | (0.35) |
Mainz Biomed Corporate Filings
| 14th of February 2025 Other Reports | ViewVerify | |
6K | 27th of January 2025 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 16th of December 2024 Other Reports | ViewVerify | |
| 11th of December 2024 Other Reports | ViewVerify |
Mainz Stock media impact
Far too much social signal, news, headlines, and media speculation about Mainz Biomed that are available to investors today. That information is available publicly through Mainz media outlets and privately through word of mouth or via Mainz internal channels. However, regardless of the origin, that massive amount of Mainz data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Mainz Biomed news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Mainz Biomed relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Mainz Biomed's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Mainz Biomed alpha.
Mainz Biomed Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Mainz Biomed can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Mainz Biomed Corporate Management
| Corinna Gorges | Head RD | Profile | |
| Chris PMP | Chief Officer | Profile | |
| Frank KriegSchneider | Chief Officer | Profile | |
| Darin Leigh | Chief Officer | Profile | |
| Philipp Freese | Chief Officer | Profile | |
| Petra Ploesser | Head Quality | Profile | |
| Guido Baechler | CEO Director | Profile |
Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.